Carlo Maria Alfieri
Overview
Explore the profile of Carlo Maria Alfieri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abinti M, Albanesi F, Gandolfo M, Castellano G, Alfieri C, Favi E
J Nephrol
. 2024 Dec;
PMID: 39699756
No abstract available.
2.
Regalia A, Abinti M, Alfieri C, Campise M, Verdesca S, Zanoni F, et al.
Clin Kidney J
. 2024 Dec;
17(12):sfae320.
PMID: 39664990
In recent years, advancements in immunosuppressive medications and post-transplant management have led to a significant decrease in acute rejection rates in renal allografts and consequent improvement in short-term graft survival....
3.
Messa P, Sabarinath S, Alfieri C, Castellano G, Vettoretti S
G Ital Nefrol
. 2024 Nov;
41(Suppl 83).
PMID: 39503227
The important advances in scientific knowledge have led to a notable enrichment of therapeutic offers in the field of CKD-MBD, which have allowed better control of the related biochemical parameters...
4.
Alfieri C, Molinari P, Cinque F, Vettoretti S, Cespiati A, Bignamini D, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39062970
Diabetes mellitus (DM) significantly impacts renal and hepatic function, necessitating comprehensive understanding and management strategies. Renal involvement, namely diabetic kidney disease (DKD), presents a global challenge, with increasing prevalence paralleling...
5.
Abinti M, Vettoretti S, Caldiroli L, Mattinzoli D, Ikehata M, Armelloni S, et al.
J Clin Med
. 2024 Jul;
13(13).
PMID: 38999530
: In patients with chronic kidney disease (CKD), Fibroblast Growth Factor 23 (FGF23) is markedly increased and has been proposed to interact with systemic inflammation. : In this cross-sectional study,...
6.
Perna A, Campise M, Alfieri C, Regalia A, Cresseri D, Gandolfo M, et al.
J Nephrol
. 2024 Jun;
37(6):1611-1619.
PMID: 38833076
Background: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare disease with limited data on outcomes after transplantation. Methods: In this single-center retrospective cohort study, we describe the outcomes of...
7.
Mattinzoli D, Turolo S, Ikehata M, Vettoretti S, Montini G, Agostoni C, et al.
J Clin Med
. 2023 Sep;
12(18).
PMID: 37762869
During chronic kidney disease (CKD) progression, an increase in fibroblast growth factor (FGF23) is present. In stage 5, a positive correlation between FGF23 and omega-6 (n-6) polyunsaturated fatty acids (PUFAs)...
8.
Abinti M, Favi E, Alfieri C, Zanoni F, Armelloni S, Ferraresso M, et al.
Am J Transplant
. 2023 Jul;
23(11):1673-1693.
PMID: 37517555
Kidney transplantation (KT) is the best treatment for end-stage kidney disease. However, early diagnosis of graft injury remains challenging, mainly because of the lack of accurate and noninvasive diagnostic techniques....
9.
Messa P, Castellano G, Vettoretti S, Alfieri C, Giannese D, Panichi V, et al.
Nutrients
. 2023 Apr;
15(7).
PMID: 37049567
Patients with urolithiasis, and particularly those with hypercalciuria, frequently have a marked reduction of bone mineral content up to the levels of osteoporosis, with a significant increase in bone fracture...
10.
Mattinzoli D, Li M, Castellano G, Ikehata M, Armelloni S, Elli F, et al.
Front Med (Lausanne)
. 2022 Dec;
9:1038638.
PMID: 36569120
Introduction: High serum levels of fibroblast growth factor 23 (FGF23) characterize chronic kidney disease (CKD) since its early stages and have been suggested to contribute to inflammation and cardiovascular disease....